To use all functions of this page, please activate cookies in your browser.
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
239 Current news about the topic monoclonal antibodiesrss
|You can refine your search further. Select from the filter options on the left to narrow down your results.|
Communication between immune cells determines response to vaccination
Immunosuppressed patients often cannot build up good protection after a vaccination because the necessary cells of the immune system function less well or are not present at all. This has been studied especially in the drug therapy of rheumatoid arthritis. Scientists from TWINCORE and the ...
How the membrane protein CD20 keeps the immune system’s antibody-producing cells in check
Rituximab, an anti-cancer drug targeting the membrane protein CD20, was the first approved therapeutic antibody against B tumor cells. Immunologists at the University of Freiburg have now solved a mystery about how it works. A team headed by Professor Dr. Michael Reth used cell cultures, healthy ...
Monoclonal antibody and experimental drug given to patients promoted rapid improvement of respiratory function in patients in severe condition
Two independent clinical studies – one by researchers at the Center for Cell-Based Therapy (CTC) in Ribeirão Preto, state of São Paulo (Brazil), on the monoclonal antibody eculizumab, and the other by scientists at the University of Pennsylvania in Philadelphia (USA) on an experimental drug ...
Contract valued up to $ 18.2 m
Evotec SE announced that the U.S. Department of Defense (“DOD”) awarded its Seattle-based subsidiary, Just – Evotec Biologics, Inc. a contract valued up to $ 18.2 m to develop and manufacture monoclonal antibodies (“mAbs”) for treatment and/or prevention of COVID-19. The goal of this programme is ...
Companies to collaborate on mRNA vaccine and monoclonal antibody research programmes in infectious diseases
GlaxoSmithKline plc and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens. The collaboration complements ...
Herceptin was the first monoclonal antibody that blocks a cancer causing protein. For the invention of Herceptin and the development of a life-saving therapy for women with breast cancer, three researchers are now receiving the Lasker~DeBakey Clinical Medical Research Award: Axel Ullrich, ...
Merck awarded a grant known as the Future Insight Prize for the first time
Merck awarded a grant known as the Future Insight Prize for the first time. Pardis Sabeti, Harvard University and the Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA, and James Crowe, Vanderbilt University Medical Center, Nashville, Tennessee, USA, were recognized for their ...
Scientists at the German Centre for Cardiovascular Research (DZHK) have started a study to find out whether a monoclonal antibody restoring vascular integrity is safe and has positive effects on organ functions of patients with cardiogenic shock. The multicenter trial is sponsored by the ...
ALENTIS Therapeutics raising CHF 12.5m in a Series A to develop novel therapeutics in advanced liver disease and cancer
ALENTIS Therapeutics, a Swiss-French biotech company developing novel therapeutics in advanced liver disease and cancer, announced the completion of a Series A financing of CHF 12.5million (Euro 11.1m; USD 12.5m). The Swiss venture capital firms BioMedPartners and BB Pureos Bioventures co-led the ...
Janssen has Expanded Clinical Development of Guselkumab into Familial Adenomatous Polyposis
MorphoSys AG announced that its licensee Janssen Research & Development, LLC, has further expanded the clinical development of guselkumab (Tremfya(R)) into familial adenomatous polyposis (FAP), a disease of the gastrointestinal tract. Janssen has initiated a phase 1b proof-of-concept clinical ...